brand:
XOLAIR®
manufacturer:
Novartis
active substances:
OMALIZUMAB
strength:
150mg/ml
pack size:
1 x 1ml Syringe
XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat chronic rhinosinusitis with nasal polyps (CRSwNP) in people 18 years of age and older when medicines to treat CRSwNP called nasal corticosteroids have not worked well enough.